Amplia Therapeutics CEO outlines 2023 milestones

Melbourne, Victoria –Information Direct– Amplia Therapeutics Ltd

Amplia Therapeutics Ltd (ASX:ATX) CEO Dr Chris Burns speaks with Proactive following his transfer into the management position late final 12 months. Amplia is an Australian pharmaceutical firm advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for most cancers and fibrosis. FAK is an more and more vital goal in most cancers and Amplia has a specific growth focus in fibrotic tumours corresponding to pancreatic and ovarian cancers.

Contact Particulars

Proactive Buyers

Jonathan Jackson

+61 413 713 744

[email protected]

View supply model on

Previous post Talonvest Arranges $73.7 Million Financing for 9-Property, Multi-State Self-Storage Portfolio
Next post World report highlights hyperlink between corruption, violence